S1R is expressed primarily in cerebral cortex, hippocampus, and cerebellum Purkinje cells (7, 8), and has been proposed as a target for treatment of central nervous system diseases, including amnesia, pain, schizophrenia, clinical depression, Alzheimer disease, stroke, and addiction (9, 10). This evidence concerns the gene TMBIM4 and schizophrenia.